Skip to main content

Towards Early diagnosis and biomarker validation in Arthritis Management

Objective

An ideal intervention in a chronic inflammatory disease such as Rheumatoid Arthritis (RA) would be a preventive one. In order to develop preventive strategies and therapies two key developments need to occur: (1) Biomarkers need to be identified that can be used to predict an individual’s risk of developing RA. (2) Modifiable disease mechanisms need to be identified and characterized in the early phases of disease. The key objective of the TEAM consortium is to specifically identify diagnostic biomarkers and disease mechanisms operating during the transition from health to rheumatoid arthritis. Our consortium will achieve this by developing a collaborative, integrated programme of work that links researchers with key SMEs involved in biomarker development to produce a “personalized predictive bioprofile” for patients destined to develop RA. The Euro-TEAM consortium will deliver a step change in the development of biomarkers and diagnostic kits that are timely, strategically important for European SMEs, and based on a disease (RA) in which concrete genetic and environmental risk factors have already been established. Firstly, it will directly compare biomarkers in the preclinical phases of disease with established markers in the clinical phases. Secondly, it will look beyond the synovium interrogating lymphoid, lung and periodontal tissue in a first-in-class approach to measuring systemic changes in the earliest phases of disease. Thirdly, it will place great emphasis on understanding why synovial inflammation resolves in some individuals and develop biomarkers of this “reverse” phase. Fourthly, it will explore a key cell type (stromal cells) that has been almost completely ignored in current biomarker studies. Finally, it will directly involve patients and other specialists, particularly from the fields of genetics, ethics and patient and public involvement in helping to visualize and communicate risk following a positive biomarker test.

Field of science

  • /humanities/philosophy, ethics and religion/ethics
  • /natural sciences/biological sciences/genetics and heredity

Call for proposal

FP7-HEALTH-2012-INNOVATION-1
See other projects for this call

Funding Scheme

CP-FP - Small or medium-scale focused research project

Coordinator

THE UNIVERSITY OF BIRMINGHAM
Address
Edgbaston
B15 2TT Birmingham
United Kingdom
Activity type
Higher or Secondary Education Establishments
EU contribution
€ 1 245 220
Administrative Contact
Erica Conway (Ms.)

Participants (15)

UNIVERSITAT ZURICH
Switzerland
EU contribution
€ 357 800
Address
Ramistrasse 71
8006 Zürich
Activity type
Other
Administrative Contact
Renate Gay (Prof.)
ACADEMISCH ZIEKENHUIS LEIDEN
Netherlands
EU contribution
€ 417 600
Address
Albinusdreef 2
2333 ZA Leiden
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Joyce Kuijper (Mrs.)
KAROLINSKA INSTITUTET
Sweden
EU contribution
€ 358 040
Address
Nobels Vag 5
17177 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Caroline Hamilton (Mrs.)
ACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM
Netherlands
EU contribution
€ 351 970
Address
Meibergdreef 15
1105AZ Amsterdam
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Erwin J. Van Der Meijden
MEDIZINISCHE UNIVERSITAET WIEN
Austria
EU contribution
€ 252 800
Address
Spitalgasse 23
1090 Wien
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Klaus Machold (Prof.)
UNIVERSITY OF LEEDS
United Kingdom
EU contribution
€ 218 000
Address
Woodhouse Lane
LS2 9JT Leeds
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Martin Hamilton (Mr.)
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany
EU contribution
€ 218 000
Address
Chariteplatz 1
10117 Berlin
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Eveline Fräßdorf (Ms.)
UNIVERSITY OF GLASGOW
United Kingdom
EU contribution
€ 158 000
Address
University Avenue
G12 8QQ Glasgow
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Derek Motherwell (Mr.)
UNIVERSITATSKLINIKUM ERLANGEN
Germany
EU contribution
€ 158 000
Address
Maximiliansplatz 2
91054 Erlangen
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Katrin Faber (Dr.)
THE UNIVERSITY OF MANCHESTER
United Kingdom
EU contribution
€ 549 999
Address
Oxford Road
M13 9PL Manchester
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Katherine Boylan (Dr.)
KUNGLIGA TEKNISKA HOEGSKOLAN
Sweden
EU contribution
€ 210 200
Address
Brinellvagen 8
100 44 Stockholm
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Peter Nilsson (Prof.)
Arthrogen BV

Participation ended

Netherlands
EU contribution
€ 236 295
Address
Meibergdreef
1105 BA Amsterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Margriet Vervoordeldonk (Dr.)
ORGENTEC DIAGNOSTIKA GMBH
Germany
EU contribution
€ 347 850
Address
Carl Zeiss Strasse 49
55129 Mainz
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Friederike Hammar (Dr.)
ISLENSK ERFDAGREINING EHF
Iceland
EU contribution
€ 518 800
Address
Sturlugotu 8
101 Reykjavik
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Administrative Contact
Frosti Jonsson (Mr.)
UPPSALA UNIVERSITET
Sweden
EU contribution
€ 178 800
Address
Von Kraemers Alle 4
751 05 Uppsala
Activity type
Higher or Secondary Education Establishments
Administrative Contact
Mats G Hansson (Prof.)